Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product - PubMed (original) (raw)
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
H Kiyoi et al. Leukemia. 1998 Sep.
Abstract
An internal tandem duplication (ITD) of the FLT3 gene is found in nearly 20% of acute myeloid leukemia (AML) and 5% of myelodysplastic syndrome cases. Our serial studies on 51 samples with the FLT3 gene mutation indicated that the ITD was frequently (47/51) clustered in the tyrosine-rich stretch from codon 589 to 599 and rarely (3/51) in its downstream region, both of which are located within the juxtamembrane (JM) domain. One remaining sample had an insertion into the JM domain of nucleotides of unknown origin. To elucidate the biological relevance of the ITD or the insertion, we expressed various types of mutant FLT3 in Cos 7 cells. All mutant FLT3 studied were ligand-independently dimerized and their tyrosine residues were phosphorylated. The Y589 of FLT3 was essential for the phosphorylation in the wild FLT3, but a Y589F conversion did not affect the phosphorylation status of the mutant FLT3. These findings suggest that the elongation of the JM domain rather than increase of tyrosine residues causes gain-of-function of FLT3. Thus, ITD is a novel modality of somatic mutation which activates its product. Since the DNA corresponding to codon 593 to 602 potentially forms a palindromic intermediate, we propose that a DNA-replication error might be associated with generating the ITD of the FLT3 gene.
Similar articles
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. Yamamoto Y, et al. Blood. 2001 Apr 15;97(8):2434-9. doi: 10.1182/blood.v97.8.2434. Blood. 2001. PMID: 11290608 - Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Jilani I, et al. Leukemia. 2003 Jan;17(1):114-9. doi: 10.1038/sj.leu.2402743. Leukemia. 2003. PMID: 12529667 - Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Kiyoi H, et al. Oncogene. 2002 Apr 11;21(16):2555-63. doi: 10.1038/sj.onc.1205332. Oncogene. 2002. PMID: 11971190 - FLT3 in human hematologic malignancies.
Kiyoi H, Naoe T. Kiyoi H, et al. Leuk Lymphoma. 2002 Aug;43(8):1541-7. doi: 10.1080/1042819021000002866. Leuk Lymphoma. 2002. PMID: 12400596 Review. - FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
Reilly JT. Reilly JT. Leuk Lymphoma. 2003 Jan;44(1):1-7. doi: 10.1080/1042819021000040233. Leuk Lymphoma. 2003. PMID: 12691136 Review.
Cited by
- Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA, Long MD, Kosaka Y, Long N, Mulkey JS, Coy JL, Agarwal A, Lind EF. Flynn PA, et al. Front Immunol. 2024 Mar 1;15:1297338. doi: 10.3389/fimmu.2024.1297338. eCollection 2024. Front Immunol. 2024. PMID: 38495876 Free PMC article. - Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements.
Schieffer KM, Moccia A, Bucknor BA, Stonerock E, Jayaraman V, Jenkins H, McKinney A, Koo SC, Mathew MT, Mardis ER, Lee K, Reshmi SC, Cottrell CE. Schieffer KM, et al. Cancers (Basel). 2023 Sep 2;15(17):4394. doi: 10.3390/cancers15174394. Cancers (Basel). 2023. PMID: 37686670 Free PMC article. - Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.
Bogdanov K, Kudryavtseva E, Fomicheva Y, Churkina I, Lomaia E, Girshova L, Osipov Y, Zaritskey A. Bogdanov K, et al. Pathophysiology. 2023 Aug 1;30(3):296-313. doi: 10.3390/pathophysiology30030024. Pathophysiology. 2023. PMID: 37606386 Free PMC article. - FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile.
Garciaz S, Hospital MA. Garciaz S, et al. Onco Targets Ther. 2023 Jan 19;16:31-45. doi: 10.2147/OTT.S236740. eCollection 2023. Onco Targets Ther. 2023. PMID: 36698434 Free PMC article. Review. - BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells.
Romine KA, MacPherson K, Cho HJ, Kosaka Y, Flynn PA, Byrd KH, Coy JL, Newman MT, Pandita R, Loo CP, Scott J, Adey AC, Lind EF. Romine KA, et al. Leukemia. 2023 Mar;37(3):580-592. doi: 10.1038/s41375-023-01808-0. Epub 2023 Jan 21. Leukemia. 2023. PMID: 36681742 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous